Lineage Cell Therapeutics (LCTX) Net Income towards Common Stockholders Growth (5y) (2015 - 2026)
Lineage Cell Therapeutics (LCTX) Net Income towards Common Stockholders Growth (5y) (2015 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Lineage Cell Therapeutics | 270.61 Mn | 212.77 Mn | 1.07 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -25.75% |
| Mar 31, 2026 | -27.15% |
| Dec 31, 2025 | -55.08% |
| Sep 30, 2025 | -18.84% |
| Jun 30, 2025 | -28.11% |
| Mar 31, 2025 | 4.17% |
| Dec 31, 2024 | -18.89% |
| Sep 30, 2024 | 30.50% |
| Jun 30, 2024 | 29.23% |
| Mar 31, 2024 | -17.24% |
| Dec 31, 2023 | 36.41% |
| Sep 30, 2023 | -16.08% |
| Jun 30, 2023 | -2.29% |
| Mar 31, 2023 | 41.39% |
| Dec 31, 2022 | 39.32% |
| Sep 30, 2022 | -18.37% |
| Jun 30, 2022 | 15.88% |
| Mar 31, 2022 | -16.43% |
| Dec 31, 2021 | -40.73% |
| Sep 30, 2021 | -17.62% |